<code id='E378E880F7'></code><style id='E378E880F7'></style>
    • <acronym id='E378E880F7'></acronym>
      <center id='E378E880F7'><center id='E378E880F7'><tfoot id='E378E880F7'></tfoot></center><abbr id='E378E880F7'><dir id='E378E880F7'><tfoot id='E378E880F7'></tfoot><noframes id='E378E880F7'>

    • <optgroup id='E378E880F7'><strike id='E378E880F7'><sup id='E378E880F7'></sup></strike><code id='E378E880F7'></code></optgroup>
        1. <b id='E378E880F7'><label id='E378E880F7'><select id='E378E880F7'><dt id='E378E880F7'><span id='E378E880F7'></span></dt></select></label></b><u id='E378E880F7'></u>
          <i id='E378E880F7'><strike id='E378E880F7'><tt id='E378E880F7'><pre id='E378E880F7'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive